Jump to any asset
850 assets, updated daily
As of September 10, 2026, McKesson Corporation (MCK) trades at $880.86. CleaRank Financial AI rates it Buy with a fair value of $1,000.00, 13.5% above the current price. Wall Street's consensus target is $1,000.00 across 18 analysts. RSI at 60 is in neutral territory, and the price is above its 50-day average of $852.64.
McKesson Corporation (MCK)
McKesson Corporation NYSE
$880.86
-10.82 (-1.21%)
Latest Price
AI Analyst Consensus
74 / 100
McKesson Corporation (MCK) is trading at $891.68, above its 50-day and 200-day moving averages ($852.64 and $843.56), indicating positive price momentum. The company has a strong track record of beating earnings estimates, most recently reporting an EPS of $9.93 against an estimate of $9.54 for the August 2026 quarter. With a consensus rating of Buy and a median analyst price target of $1000, MCK presents a compelling investment case within the Healthcare sector. Revenue growth has been consistent, with the current year's estimate at $431.9 billion, representing a 7.00% year-over-year increase. The stock's RSI is at 60.29, signaling bullish momentum. While the company exhibits strong operational performance, investors should monitor the significant insider selling activity, with $83.6 million in total sales reported.
MCK Price Analysis
Market Metrics
Open
$899.77
Day Range
$879.24 to $904.74
Prev Close
$891.68
Volume
809.6K
52-Week Range
$677.28 to $999.00
Market Cap
$103.96B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (0.0192% difference), suggesting fair market pricing relative to industry standards.
MCK Analysis
Company's Health
4/5
12-Month Analyst Target
+13.53% Upside
Median of 18 analysts (12-month)
$1,000.00
AI Technical Analysis
McKesson Corporation (MCK) is trading above its 50-day and 200-day moving averages ($852.64 and $843.56), and its 20-day exponential moving average ($886.75), suggesting an upward trend. The Relative Strength Index (RSI) is at 60.29, indicating bullish momentum, and the MACD is positive at 14.68. Volume has been slightly above average, with the latest volume at 972,400 compared to the average of 921,590. Key support levels are indicated by the moving averages, with resistance likely to be tested near the current price. The chart structure suggests continued strength, though the heavy insider selling warrants attention as a potential counter-signal to the bullish technicals.
ProTips
- Monitor insider transaction activity closely, as the recent heavy selling by insiders warrants caution despite bullish technical signals.
- McKesson Corporation (MCK) operates in the Healthcare sector, which is generally considered defensive, but specific regulatory changes impacting drug distribution could affect performance.
- Consider position sizing carefully given the significant insider selling and the stock's current trading range above its 50-day and 200-day moving averages ($852.64 and $843.56).
Key Catalysts
Bullish
Consistent Earnings Beats
McKesson Corporation (MCK) has a strong history of exceeding analyst EPS estimates, most recently with a 4.09% beat in August 2026. This pattern suggests operational efficiency and strong demand for its services.
Source: Earnings ReportsBullish
Positive Analyst Consensus and Price Targets
With a 'Buy' consensus rating from 18 analysts and a median price target of $1000, Wall Street views McKesson favorably, indicating potential upside from the current price.
Source: Wall Street AnalystsBearish
Heavy Insider Selling
Insiders have sold $83.6 million worth of stock, signaling potential concerns or a reassessment of future prospects by management, which could weigh on the stock price.
Source: Insider TransactionsNeutral
Steady Revenue Growth Projections
Projected 7.00% revenue growth for the current quarter and year indicates stable business expansion, providing a baseline for performance.
Source: Revenue EstimatesMarket Outlook
McKesson Corporation (MCK) is expected to maintain its positive trajectory over the next 6-12 months, driven by its consistent revenue growth and strong earnings performance. The median analyst price target of $1000 suggests an upside potential of 12.1% from the current price of $891.68. The company's ability to consistently beat earnings estimates and its bullish technical indicators provide a solid foundation for this outlook. Potential catalysts for upside include continued market share gains in healthcare distribution and successful integration of any new strategic initiatives. Conversely, significant insider selling remains a key risk that could pressure the stock, alongside potential regulatory shifts or intensified competition within the sector. Monitoring these factors will be key for assessing the stock's future performance.
Key Statistics
| Market Cap | 103.96B |
|---|---|
| P/E Ratio | 23.84 |
| EPS (TTM) | 37.32 |
| Dividend Yield | 0.3810% |
| 52 Week High | 999.00 |
| 52 Week Low | 677.28 |
McKesson Corporation (MCK) trades at a P/E ratio of 23.84, which appears reasonable given its sector and growth profile. The company's revenue growth is projected at 7.00% for the current quarter and year, reaching an estimated $431.9 billion for the current year. This growth is supported by consistent earnings beats, with the latest quarter showing an EPS of $9.93 versus an estimate of $9.54. The company's profitability metrics, such as a projected ROE of 15.0% and a healthy revenue growth of 7.7%, align with sector averages. The consistent revenue and earnings performance suggest a fundamentally sound business. The current valuation is supported by these growth indicators and analyst expectations.
Earnings & Growth Analysis
McKesson Corporation (MCK) has demonstrated a strong pattern of exceeding analyst earnings expectations. In the most recent quarter ending August 2026, the company reported an EPS of $9.93, surpassing the estimate of $9.54 by 4.09%. This follows a trend of positive surprises in prior quarters, including a 6.02% beat in the July 2026 quarter and a 1.04% beat in May 2026. The significant 16.52% price increase following the February 2026 earnings report highlights the market's positive reaction to these consistent earnings beats.
Key Risks
McKesson Corporation (MCK) faces significant risk from heavy insider selling, with $83.6 million in total sales reported by insiders, indicating a potential lack of confidence at management levels despite bullish technicals. While the stock is trading above key moving averages and showing bullish momentum, the substantial insider dispositions could signal headwinds or a reassessment of future growth prospects. Investors should also consider the competition within the medical distribution sector, where pricing pressures and regulatory changes can impact margins.
Technical Indicators
| RSI (14) | 60.29 |
|---|---|
| MACD | 14.68 |
| SMA 50 | 852.64 |
| SMA 200 | 843.56 |
RSI
Bullish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($852.64) above the 200-day SMA ($843.56), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.01
Weak correlation
Nasdaq 100 (QQQ)
-0.09
Weak correlation
Bitcoin (BTC)
-0.09
Weak correlation
Gold (XAU)
-0.01
Weak correlation
Check Custom Correlation
Calculating correlation...
MCK Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
🟢 LONG ENTRY (click to switch)
CONSERVATIVE
$863.24
2% below current price (Pullback entry)
Lower risk, wait for pullback
AGGRESSIVE
$880.86
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$825.69
MAX LOSS
-4.4%
Volatility-Adjusted Stop Loss
Calculated based on RSI (60.3) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$906.40
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$949.57
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$992.73
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for MCK is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in MCK in September 2016 would be worth about $49,409 today, compared with about $35,241 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MCK today could grow to about $30,643 by 2036 in the base case, with a bull case near $100,308 and a bear case around $9,361. Projections are statistical simulations, not guarantees.
MCK Stock Price Prediction: 2030
CleaRank's simulation projects a price near $1,379 for MCK by 2030 in the base case, from $881 today (1.6x over 4 years). The downside path ends near $651. These are outcomes of a Monte Carlo simulation run on MCK's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $677 | $985 | $1,434 |
| 2028 | $648 | $1,102 | $1,873 |
| 2029 | $644 | $1,233 | $2,360 |
| 2030 | $651 | $1,379 | $2,918 |
| 2031 | $667 | $1,542 | $3,566 |
| 2032 | $688 | $1,725 | $4,321 |
| 2033 | $715 | $1,929 | $5,203 |
| 2034 | $747 | $2,158 | $6,232 |
| 2035 | $783 | $2,413 | $7,433 |
| 2036 | $825 | $2,699 | $8,836 |
Method: 10,000 simulated price paths using MCK's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
MCK Insider Trading Analysis
Bought
None
No open-market buys
Sold
$83.6M
32 Transactions
Insiders
11
Active Traders
Avg Transaction
$2.6M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 27, 2017 | HAMMERGREN JOHN H
Chief Executive Officer
|
Sell | 300.0K | $46.4M |
| Sep 22, 2017 | HAMMERGREN JOHN H
Chief Executive Officer
|
Sell | 225.0K | $34.1M |
| Sep 29, 2017 | HAMMERGREN JOHN H
Chief Executive Officer
|
Sell | 199.0K | $30.6M |
| Jul 11, 2025 | TYLER BRIAN SCOTT
Chief Executive Officer
|
Sell | 19.4K | $13.7M |
| Jun 6, 2025 | TYLER BRIAN SCOTT
Chief Executive Officer
|
Sell | 19.4K | $13.7M |
| Oct 9, 2023 | TYLER BRIAN SCOTT
Chief Executive Officer
|
Sell | 28.7K | $12.8M |
| Nov 3, 2021 | SCHECHTER LORI A
General Counsel
|
Sell | 54.4K | $11.9M |
| Nov 7, 2023 | TYLER BRIAN SCOTT
Chief Executive Officer
|
Sell | 24.0K | $11.0M |
| Sep 8, 2023 | TYLER BRIAN SCOTT
Chief Executive Officer
|
Sell | 25.2K | $10.7M |
| Dec 14, 2017 | HAMMERGREN JOHN H
Chief Executive Officer
|
Sell | 65.0K | $10.4M |
Page 1 of 1
Frequently Asked Questions
Is McKesson Corporation (MCK) stock a buy right now?
McKesson Corporation (MCK) is currently rated a Buy with a consensus score of 74 out of 100. The stock is trading above its key moving averages, showing bullish momentum, and analysts have a median price target of $1000, offering a 12.1% upside from the current price of $891.68.
What is McKesson Corporation's (MCK) price target for 2030?
Based on Monte Carlo simulations, McKesson Corporation's (MCK) stock price is projected to reach a base case of $1395.54 by 2030, with a downside projection of $659.21 and an upside projection of $2954.33. These figures represent statistical outcomes and are not guarantees.
How has McKesson Corporation (MCK) performed in recent earnings reports?
McKesson Corporation (MCK) has consistently beaten earnings estimates. Most recently, for the August 2026 quarter, EPS was $9.93 against an estimate of $9.54, a 4.09% surprise. This follows a pattern of positive surprises in previous quarters.
What is the revenue growth outlook for McKesson Corporation (MCK)?
McKesson Corporation (MCK) is expected to see revenue growth of approximately 7.00% for the current quarter and current year, with current year revenue estimates reaching $431.9 billion. This indicates a steady expansion in the company's top line.
What are the key risks for McKesson Corporation (MCK) investors?
A primary risk for McKesson Corporation (MCK) investors is the significant insider selling activity, totaling $83.6 million, which could signal management's concerns about future performance. Additionally, competitive pressures within the healthcare distribution sector and potential regulatory changes pose ongoing risks.
How does McKesson Corporation (MCK) compare to its sector averages?
McKesson Corporation (MCK) shows a P/E ratio of 23.84 and revenue growth of 7.7%, aligning with sector averages. Its projected ROE is 15.0%, and while debt-to-equity is estimated at 0.8, specific sector average data for Price-to-Sales is not directly comparable without further context.
What is the dividend yield for McKesson Corporation (MCK)?
McKesson Corporation (MCK) offers a dividend yield of approximately 0.38%, with a dividend rate of $3.40. This suggests a modest income component for investors, complementing potential capital appreciation.